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ABSTRACT
Statins are one of the most heavily prescribed medications. The 2018 ACC/AHA guidelines support
statin therapy for most older adults, but recommendations are less clear for those over 75. The
literature was systematically reviewed for evidence of the efficacy of statin treatment in different
patient populations. Significant evidence was found supporting a decreasing association between
low-density lipoprotein cholesterol (LDL-C) and mortality as well as decreasing statin efficacy with
increasing age. The consequences of unnecessary statin therapy can be severe for older adults.
Improved methods for evaluating atherosclerotic cardiovascular disease (ASCVD) risk, such as using




Statins are often prescribed using a treat-all approach to prevent ASCVD. Despite such widespread use, available
evidence does not support the use of statins for primary prevention in very old adults without diabetes. The risk of
adverse events is amplified in the elderly population. Healthcare providers could do better to balance the benefits and
harms of statin therapy, and treatment recommendations should be individualized for this population. For predicting
ASCVD risk, metrics such as CAC are superior to plasma LDL-C and the Framingham risk calculator, which is heavily
weighted for age. Future steps in our analysis will involve assessing evidence for the U.S. Preventive Services Task Force
recommendation to raise the 10-year risk threshold for treatment from 7.5% to 10% for adults 40–75 with no history of
ASCVD.
Plasma LDL-C has been the principal target of cholesterol-lowering therapy for the past three
decades, and statins are effective in lowering LDL-C. Data on the relationship between LDL-C and
mortality, however, reveal a paradoxical relationship between LDL-C and ASCVD. In 2016, Ravnskov
et al. conducted a review of 19 clinical studies involving 68,094 patients 60 years or older. In 16
different cohorts accounting for 92% of participants, an inverse association was found between
LDL-C and all-cause mortality. A population study of 269,391 Korean adults over 40 revealed that
changes in total cholesterol within a two-year period increased the risk of subsequent all-cause
mortality relative to those who maintained levels in the second tertile.3
Among the elderly, frailty and poor health status likely contribute to increased risk of death in
those with low cholesterol. Low cholesterol can also be a marker of severe diseases such as cancer.
In the general population, LDL is not the best ASCVD predictor. LDL-C was dropped from the 2008
Framingham calculator for 10-year ASCVD risk because it did not improve the model fit. LDL-C is a
confounded variable, consisting of several subclasses of particles of different sizes and densities.
Small-dense LDL and covalently modified lipoprotein(a) are considerably more atherogenic than
larger LDL particles. Other blood lipids such as triglycerides, apolipoprotein B, HDL, and remnant
cholesterol are now emerging as more useful ASCVD predictors.
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SPECIAL  CONSIDERATIONS
Adverse Musculoskeletal Effects
Muscle weakness can be serious adverse effects in the elderly, potentially leading to life-threatening falls or
severe injury.4 For muscle pain, estimates of the 5-year number needed to harm (NNH) vary from 19 to 47.
Statins deplete endogenous levels of coenzyme Q. Ubiquinol supplemention may provide protective benefits.
Cognition
Despite the Food and Drug Administration’s 2012 warning about memory loss in statins, meta-analysis of 25
RCTs indicated that statins are not associated with cognitive impairment.6
New-Onset Diabetes
Statins can increase blood glucose and long-term statin use increases the risk of developing diabetes relative to
non-users (RR: 1.44, 95% CI: 1.31–1.58).5 High potency statins had the highest risk (rosuvastatin, RR: = 1.61, 95%
CI: 1.30−1.98). 1-year NNH: atorvastatin=172, rosuvastatin=210, simvastatin=363 (Carter 2013).
Drug Interactions
Over 36% of older adults take ≥5 prescription medications. Atorvastatin and simvastatin are metabolized by
CYP3A4, which metabolizes half of all drugs on the market. St. John’s Wort induces CYP3A4, while grapefruit is
an inhibitor. Myopathy risk may be increased by drug interactions from polypharmacy as well as comorbidities.
INTRODUCTION
Cardiovascular disease, a leading cause of morbidity, accounts for 1 in 3 deaths in U.S. adults. Statin
drugs have become a mainstay in the primary prevention and treatment of ASCVD. From 2002 to
2013, statin use among US adults 40 years and older increased by 80%, from 18% of the general
population to 28% (39 million individuals). The Medical Expenditure Panel Survey found that statin
use for primary prevention in adults 80 years and older increased 4-fold, from 9% in 1999 to 34% in
2012. Recent meta- and post-hoc analyses have attempted to address whether available clinical
evidence supports such widespread statin use.
Early statin trials excluded elderly patients, and less evidence exists for the efficacy of statins in this
heterogenous clinical group.1 Statins are associated with adverse musculoskeletal event: myopathy,
muscle weakness and pain, arthropathies, and rhabdomyolysis. This is problematic for the elderly,
in whom statins can contribute to deconditioning and frailty. The current literature reflects a
complex relationship between statin efficacy and patient age. While no randomized control trials
(RCTs) have been conducted of patients older than 80 years at baseline, the independent STAREE
trial (NCT02099123) is currently assessing high intensity statin therapy in adults 70 and older.2
RELATION BETWEEN CHOLESTEROL AND CLINICAL OUTCOMES
SECONDARY PREVENTION IN THE ELDERLY

































* Primary prevention, i.e., no history of ASCVD. According to the 2013 ACC/AHA cholesterol 
guidelines, most of the population was eligible for statin treatment [10% ASCVD risk at 10 years 
(Ramos 2018)].
Ramos et al. conducted a retrospective cohort
study of 46,864 participants 75 years and older
with no history of ASCVD. To prevent survivor
bias, new statin users were selected rather than
all statin users. A Cox proportional regression
model was used to calculate the hazard ratios of
statin use for outcome events. Statins were
effective in reducing all-cause mortality [1-year
number needed to treat (NNT): 306] and the
incidence of ASCVD (NNT: 164) in diabetic
patients aged 75−84 (Table 1). The reduction in
ASCVD began to lose statistical significance at
age 85 and disappeared completely at age 92.
The protective effect of statins against all-cause
mortality in began to lose significance at age 82
in diabetes patients and disappeared definitively
at age 88. Remarkably, statins did not reduce
ASCVD or all-cause mortality in patients ≥75
without diabetes.
The meta-analysis by Ponce et al. also assessed the effect of statins in the treatment of patients diagnosed with clinically significant
ASCVD. In contrast to primary prevention, high-certainty evidence was obtained for the use of statins in adults 65 and over for
secondary prevention of ASCVD. Compared to placebo, statins significantly decreased the risk of all-cause mortality (RR: 0.80, 95% CI:
0.73–0.89), cardiovascular mortality (RR: 0.68, 95% CI: 0.58–0.79), CAD (RR: 0.68, 95% CI: 0.61–0.77), and myocardial infarction (RR:
0.68, 95% CI: 0.59–0.79). No separate data on subgroups, such as those specifically over 75 years of age or patients with type 2
diabetes, was available from the eight trials reviewed.
The severity of CAD and plaque formation can be assessed based on the level of coronary
artery calcification (CAC) in a computed tomography scan. The CAC score is a robust
independent risk factor for ASCVD and all-cause mortality. A meta-analysis was conducted of
49 studies involving 85,000 patients (Sarwar 2009). During a mean follow-up period of 50
months, 0.47% of patients with no CAC suffered a cardiovascular event, compared to 4.1% of
patients with CAC, highlighting the metric’s negative predictive power.
A retrospective cohort study of 13,644 participants assessed the impact of statins on ASCVD
outcomes stratified by baseline CAC score (Mitchell 2018). The median follow-up period was
9.4 years. Compared to those with no CAC, individuals with CAC who took a statin within 5
years of CAC testing had a lower risk of a first major adverse cardiovascular event (MACE). The
NNT depended on CAC severity (Table 2). To put this into context, a small longitudinal study of
middle-aged adults found that 22% of statin-naïve patients with CAC = 0 were eligible for
statins based on the 2013 ACC/AHA guidelines (Pursnani 2015).
CAC 
Score
HR (95% CI) NNT *
0 1.00  (0.79-1.27) -
>0 0.76  (0.60-0.95) -
1−100 0.83  (0.60-1.16) 100
101−400 0.32  (0.21-0.48) 12
STATINS IN PRIMARY PREVENTION
EVIDENCE-BASED FINDINGS FOR CLINICAL PRACTICETABLE 1.  Hazard ratios (HR) in new statin users vs. non-statin users.*
TABLE 2.  HRs for first MACE in 
statin-users vs. non-statin users.
2013 guidelines cite a 28% reduction in RR per mmol LDL-C reduction (39 mg/dL). Meta-analysis
of intensive statin therapy found a modest RR of 14% in adults with LDL > 100 (Navarese 2018).
In patients with diabetes, statins are protective for primary prevention of ASCVD up to age 85.
CAC < 10 is a strong negative risk marker that can be used to rule out statin treatment in low-
risk individuals.
In adults over 75 with no history of ASCVD or diabetes, statins have not been shown to reduce
ASCVD, stroke, or cardiovascular/all-cause mortality.
A 2019 meta-analysis by Ponce et al. included 23 RCTs comprising 60,194 patients 65 and over. For
primary prevention in those with no history of ASCVD, statins reduced the risk of coronary artery
disease [CAD; relative risk (RR): 0.79, 95% CI: 0.68–0.91] and myocardial infarction (MI; RR: 0.45,
95% CI: 0.31–0.66) but not all-cause or cardiovascular mortality (Figure 1).
Statins have not been shown to reduce mortality in adults over 65 with no history of ASCVD. Lack
of benefit in heart failure may be due to decreased coenzyme Q levels (Alehagen 2015).
Citation Study Type N Age Notable Outcomes
STATIN USERS vs. CONTROLS
Han 2017.
JAMA Intern. Med. 177:955.
ALLHAT-LLT: open-label 
RCT; North America 2,867 ≥ 65
Increased all-cause mortality [HR = 1.34 (95% CI: 0.98-1.84; P = .07)] for patients 
≥75 with moderate hyperlipidemia/hypertension taking a moderate intensity 
statin vs. usual care (primary prevention).
Ponce 2019.
J. Clin. Endocrinol. Metab. 
104:1585.
Meta-analysis, 23 trials 60,194 ≥ 65 Statins reduced the risk of all-cause and cardiovascular mortality in secondary but not primary prevention.
Ramos 2018.
BMJ 362:k3359.
Retrospective cohort, new 
user design; Spain 46,864 ≥ 75
Statins reduced ASCVD and mortality in diabetic patients younger than 82 years. No 
benefit was observed in non-diabetic patients.
Mitchell 2018.
J. Am. Coll. Cardiol. 72:3233.
Retrospective cohort 13,644 > 18 Adults who took a statin had a reduced risk of first MACE according to their baseline CAC score. Those with no CAC had no benefit.
IRRESPECTIVE OF STATIN USE
Ravnskov 2016.
BMJ Open 6:010401.






Patients with CAC > 100 had 10-fold higher CHD mortality (coronary heart disease) 
than those with CAC = 0.
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FIGURE 1. Forest plot comparing statin use relative to placebo for primary prevention of ASCVD (RRR:
ratio of RRs). *Diabetic patients were 65-75 years. Image reproduced from J. Clin. Endocrinol. Metab. 2019; 104:1585.
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*NNT for preventing MACE through 10 
years (Mitchell 2018).
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taking a statin for 
primary prevention
